Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Net Cash Flow for 16 consecutive years, with $23.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 202.49% year-over-year to $23.8 million, compared with a TTM value of -$12.7 million through Dec 2025, up 56.78%, and an annual FY2025 reading of -$12.7 million, up 56.78% over the prior year.
  • Net Cash Flow was $23.8 million for Q4 2025 at Amicus Therapeutics, down from $33.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $212.0 million in Q3 2021 and bottomed at -$146.9 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $2.8 million, with a median of $5.1 million recorded in 2023.
  • The sharpest move saw Net Cash Flow skyrocketed 417.32% in 2023, then crashed 22769.93% in 2025.
  • Year by year, Net Cash Flow stood at -$138.7 million in 2021, then dropped by 5.92% to -$146.9 million in 2022, then soared by 91.64% to -$12.3 million in 2023, then crashed by 88.88% to -$23.2 million in 2024, then soared by 202.49% to $23.8 million in 2025.
  • Business Quant data shows Net Cash Flow for FOLD at $23.8 million in Q4 2025, $33.0 million in Q3 2025, and -$32.7 million in Q2 2025.